Summary
25.05 -0.42(-1.65%)05/17/2024
AnaptysBio Inc (ANAB)
AnaptysBio Inc (ANAB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.35 | 5.51 | 24.24 | 9.23 | 55.45 | 21.36 | -64.48 | 51.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.68 | |
| Open | 25.97 | |
| High | 26.50 | |
| Low | 25.17 | |
| Volume | 320,769 | |
| Change | -0.09 | |
| Change % | -0.35 | |
| Avg Volume (20 Days) | 446,750 | |
| Volume/Avg Volume (20 Days) Ratio | 0.72 | |
| 52 Week Range | 13.36 - 27.50 | |
| Price vs 52 Week High | -6.62% | |
| Price vs 52 Week Low | 92.22% | |
| Range | -1.12 | |
| Gap Up/Down | -0.66 | |
Fundamentals | ||
| Market Capitalization (Mln) | 685 | |
| EBIDTA | 8,286,000 | |
| PE Ratio | 103.7582 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 36.86 | |
| Book Value | 13.9730 | |
| Earnings Per Share | 0.3060 | |
| EPS Estimate Current Quarter | -0.8800 | |
| EPS Estimate Next Quarter | -0.5900 | |
| EPS Estimate Current Year | 0.8300 | |
| EPS Estimate Next Year | -3.2600 | |
| Diluted EPS (TTM) | 0.3060 | |
| Revenues | ||
| Profit Marging | 0.0687 | |
| Operating Marging (TTM) | 0.0629 | |
| Return on asset (TTM) | 0.0119 | |
| Return on equity (TTM) | 0.0226 | |
| Revenue TTM | 122,164,000 | |
| Revenue per share TTM | 4.4610 | |
| Quarterly Revenue Growth (YOY) | -0.2500 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -5,025,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 103.7582 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1513 | |
| Revenue Enterprise Value | 3.8645 | |
| EBITDA Enterprise Value | 36.5806 | |
| Shares | ||
| Shares Outstanding | 27,507,900 | |
| Shares Float | 17,134,134 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.60 | |
| Institutions (%) | 105.22 | |
05/09 18:46 EST - zacks.com
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.
05/09 16:15 EST - globenewswire.com
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
05/09 16:10 EST - globenewswire.com
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.
05/09 16:05 EST - globenewswire.com
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties. Anaptys intends to utilize the proceeds of the transaction to continue the broad development of its immune cell modulators (ICMs), including its best-in-class checkpoint agonists, in heterogeneous, systemic autoimmune and inflammatory diseases.
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties. Anaptys intends to utilize the proceeds of the transaction to continue the broad development of its immune cell modulators (ICMs), including its best-in-class checkpoint agonists, in heterogeneous, systemic autoimmune and inflammatory diseases.
05/02 11:05 EST - zacks.com
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
05/01 05:56 EST - zacks.com
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
04/24 09:00 EST - prnewswire.com
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
04/15 14:19 EST - investorplace.com
BTIG Research Predicts Over 118% Rally for These 3 Stocks
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
BTIG Research Predicts Over 118% Rally for These 3 Stocks
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
04/12 19:00 EST - fool.com
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A major bank initiated coverage of the biotech. It recommended a buy, speculating that the share price could double and then some.
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A major bank initiated coverage of the biotech. It recommended a buy, speculating that the share price could double and then some.
04/09 15:41 EST - zacks.com
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
03/14 13:01 EST - zacks.com
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
03/14 10:56 EST - zacks.com
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
03/11 18:31 EST - zacks.com
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.
03/11 16:15 EST - globenewswire.com
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.
02/29 09:15 EST - globenewswire.com
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference.
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference.
02/28 11:00 EST - zacks.com
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/19 06:56 EST - zacks.com
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
01/31 09:15 EST - globenewswire.com
Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim's 6th Annual Biotechnology Conference.
Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim's 6th Annual Biotechnology Conference.
12/07 11:17 EST - zacks.com
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?
The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?
The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
11/27 16:15 EST - globenewswire.com
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals' (NASDAQ: CNTA) blood dendritic cell antigen 2Â (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals' (NASDAQ: CNTA) blood dendritic cell antigen 2Â (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.